The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. METHODS: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni-and multivariable cox regression models addressed the association of statin use with BCR. RESULTS: Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values p0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82% ± 1 for patients without statin use and 84 ± 1% for patients using statins (P ¼ 0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P ¼ 0.10) after adjusting for the effects of standard clinicopathologic features. CONCLUSIONS: In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.
INTRODUCTION
Radical prostatectomy (RP) is the most widely used treatment in patients with clinically localized prostate cancer (PC). 1 Unfortunately, up to 40% of patients experience disease recurrence during long-term follow-up (FU) despite apparently successful surgery. 2 Statins or 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors are widely used medications for hypercholesterolemia. In recent years, there is a constant increase in numbers of statin users. 3 Studies showed that lowering of lowdensity lipoprotein cholesterol significantly reduced the incidence of major vascular events such as myocardial infarction or coronary death, stroke or coronary revascularization procedure. 4 Interestingly, statin use has been associated as well with reduced cancer-related mortality. 5 The impact of statin use on the incidence and natural history of PC remains controversial. A recent meta-analysis on statin use and risk of PC including a total of 27 studies with 1.9 million male subjects provided further evidence that statins may reduce the risk of both having any PC and clinically significant PC. 6 Moreover, in PC patients treated with external-beam radiation therapy, statin use has may be associated with a reduced risk of biochemical recurrence (BCR). [7] [8] [9] However, in one study, the beneficial effect was limited to high-risk patients 9 and another could not detect any association of statin use with PC outcomes after external-beam radiation therapy. 10 A total of seven studies investigated the association of statin use with BCR in PC patients treated with RP. Of these, five studies showed no association, [11] [12] [13] [14] [15] whereas in one study statin use was associated with increased 16 and in one study with decreased 17 risk of BCR. As previous studies cover heterogeneous, limited sized cohorts, a further analysis of the association of statin use with BCR after RP for PC in a large cohort is warranted. For this purpose, we assessed a multicenter cohort of patients treated with RP for clinically localized PC. Based on the previously published literature, we hypothesized that statin use is not associated with BCR after RP for PC.
MATERIALS AND METHODS

Patient selection and data collection
This was an institutional review board-approved study, with all participating sites providing the necessary institutional data-sharing agreements before initiation of the study. A computerized databank was generated for data transfer. After combining the data sets, reports were generated for each variable to identify data inconsistencies and other data integrity problems. Through regular communication with all sites, resolution of all identified anomalies was achieved before analysis. Before analysis, the database was closed and the final data set was produced. A total of sixAustria; Department of Urology, Medical University of Graz, Graz, Austria 
Statistical analysis
Associations of statin use with categorical variables were assessed using w 2 test. Differences in continuous variables across two categories were analyzed using the Mann-Whitney U-test. BCR-free survival curves were generated using the Kaplan-Meier method; log-rank test was applied for pairwise comparison of survival. Univariable and multivariable Cox regression models addressed the association of statin use with BCR after RP. All P-values were two-sided and statistical significance was defined as a Pp0.05. Statistical analyses were performed using SPSS Statistics 20 (SPSS, IBM, Armonk, NY, USA). Table 1A shows the clinicopathologic characteristics of the 6842 patients and their association with statin use. A total of 2275 (33.3%) were taking statins at the time of RP. Statin users were older (P ¼ 0.05) and had a higher rate of positive surgical margins (PSMs; P ¼ 0.03) than patients not using statins. There were no significant differences in preoperative PSA, preoperative or RP Gleason sum, extracapsular extension, seminal vesicle invasion and lymph node metastasis between patients who used statins and those who did not.
RESULTS
Association of statin use with clinicopathologic characteristics
Association of statin use with BCR in the entire cohort Within a median FU of 25 months (interquartile range: 8-42), 538 (11.8%) patients without statin use and 240 (10.5%) patients with statin use experienced BCR ( Figure 1 ). Actuarial estimates of BCRfree survival were 92 ± 0%, 82 ± 1% and 66 ± 3% for patients without statin use and 94±1%, 84±1% and 71±3% for patients with statin use at 2, 5 and 10 years, respectively ( Figure 1 , P ¼ 0.05). In univariable cox regression analysis, statin use was associated with a decreased risk of BCR (Table 2 , hazard ratio (HR): 0.86, 95% confidence interval (CI): 0.74-1.00, P ¼ 0.05). In multivariable analyses, age, preoperative PSA, RP Gleason sum, lymph node metastasis, PSMs, stage pT3a and pT3b were significantly associated with risk of recurrence, whereas statin use did not retain its significance ( ). Actuarial estimates of BCR-free survival were 80±2%, 62±3% and 49±4% for patients without statin use and 86±2%, 71±3% and 65±4% for patients with statin use at 2, 5 and 10 years, respectively (Figure 2 , P ¼ 0.007). In patients with PSM, clinicopathologic features were comparable between statin users and non-statin users (Table 1B) . In multivariable cox regression analysis that adjusted for the effects of standard clinicopathologic features, statin use remained significantly associated with decreased risk of BCR ( Table 2 , HR: 0.76, 95% CI: 0.58-0.99, P ¼ 0.046).
BCR-free survival did not show any significant difference between statin users and non-users in patients with RP Gleason sum p6
stage pT3b (0.12) and with lymph node metastasis (P ¼ 0.97).
DISCUSSION
In our study, PC patients using statins had a lower rate of BCR than patients not taking statins in univariable, but not multivariable cox regression analyses. This observation is in line with five previously published studies [11] [12] [13] [14] [15] and a recent meta-analysis, 19 which could not reveal a significant association of statin use with BCR after RP. In contrast, Ritch et al. detected an increased risk of BCR in PC patients using statins after RP. 16 In patients classified as D'Amico low-risk category, those taking statins had a significantly shorter BCR-free survival than patients not taking statins. In contrast, statin users in the intermediate and high-risk categories had no significant difference in BCR compared with non-users. The authors attributed the higher risk of BCR in D'Amico low-risk category patients taking statins to the reduction of PSA by statins, which has been described in various studies. 20, 21 A decrease in PSA may delay PC diagnosis and lead to an upstaging of the tumor. This would suggest that statin use may mask biologically aggressive disease. This is further supported by a significantly higher rate of patients with a pathological Gleason sum X7 in statin users compared with non-statin users in the study cohort. 16 In addition, another study showed a significantly lower PSA in patients using statins and Gleason sum X7.
12 However, it may be questioned if a PSA reduction is the explanation for the unfavorable outcome of statin users in the study because the rate of patients with a pathological Gleason sum X7 was also higher in the group of statin users in a study that found statin use to be associated with favorable outcome. 17 Furthermore, our study and three other studies on the effect of statins on the outcome of PC after RP did not show a lower PSA in patients taking statins at the time of surgery. 11, 13, 14 In contrast to the results of our and other previous studies, Hamilton et al. 17 found statin use to be associated with decreased risk of BCR after RP after adjustment for clinical and pathological features. Adding Gleason-Score to their multivariable model generated the largest shift in HR for statin use. The authors found only doses X1 dose equivalent of 20 mg simvastatin to be associated with decreased risk of BCR. Age, PSA, Gleason sum and tumor stage were comparable to our study. In contrast, Hamilton et al. had a PSM rate of 45% (non-statin users) and 44% (statin users), whereas in our study, the rate of PSM was 14.3% and 16.3%, respectively. In addition, 20% of the patients in the study Statins use and prostate cancer outcomes M Rieken et al by Hamilton et al. received postoperative radiation therapy and 6% combined radiotherapy and hormonal therapy. As studies and meta-analyses have shown a beneficial effect of statins in PC patients undergoing radiotherapy, the high rate of patients with radiotherapy might have influenced study results in this subgroup. 19 To explore the influence of clinicopathologic features on the association of statin use with outcomes after RP, we performed a subgroup analysis.
In our analysis, BCR-free survival did not show any significant difference between statin users and non-users in patients when categorizing according to Gleason sum (p 6; ¼ 7; X8) without PSM, with stage pT3a and pT3b, and with lymph node metastasis. Similar findings of subgroup analysis stratified by Gleason sum or D'Amico category were reported from previous studies.
12,14 BCR was found to be lower in PC patients with PSM taking statins compared with those not taking statins. Furthermore, in the subgroup of patients with PSM, statin use was independently associated with a decreased risk of BCR. This association has not been described previously. A possible explanation for this observation is that statins may only exert their potentially 22 Statins have also been shown to significantly reduce the migration and colony formation of PC-3 cells in human bone marrow stroma. 23 Moreover, statins have been shown to inhibit proliferation, induce cell cycle arrest, induce apoptosis in vitro and inhibit angiogenesis in mice xenograft models. 24 Furthermore, statins also have anti-inflammatory properties. 25, 26 As inflammation is affecting PC growth, statins may reduce PC progression by inhibiting inflammation. In a study on patients undergoing RP, statin intake before surgery was shown to be significantly associated with reduced risk of inflammation surrounding malignant glands within RP specimens. 27 Recent evidence also suggests a role of tumor suppression through statins in high concentration by inhibition of small GTPases involved in cell proliferation, survival, inflammation, angiogenesis and metastasis. 24 However, further basic and translational research are necessary to elucidate the association between statins and PC progression in certain subgroups of patients like those with PSM.
Our study has several limitations. These include the retrospective design. As a multi-center study, the cohort of patients underwent RP by several surgeons and several pathologists analyzed the pathological specimens. However, all physicians were dedicated to uro-oncology. Furthermore, the mean FU of the study is relatively short as we experienced a high loss to FU. More specific to this study, we did not have any information on type, dosage and duration of statin intake before and after RP. Furthermore, information on the body mass index of patients was missing, so that we could not adjust for this potential prognostic factor. 28 In addition, we were not able to account for the effects of smoking and diabetes mellitus, which may have an influence on the risk of BCR and may differ by statin use. Furthermore, significant differences in the rate of PSMs between statin users and non-users may have influenced the observed in favor of statin users. Moreover, we did not adjust our subgroup analysis for multiple comparisons. Despite its limitations, our study, to the best of our knowledge, incorporates the largest cohort of patients published so far on statin use and outcomes after RP.
In conclusion, in PC patients undergoing RP, statin use was not independently associated with lower risk of BCR. The potential effect of statin use on PC development and outcome needs further investigation through epidemiologic and translational basic research.
